Buy-rated reports

588 tickers rated Buy
Ranks this page's recent reports by score.
NatWest Group plc
NWG·Financials
A ★★★★Buy
Current$18.94
Target$23.01
Return+21.5%
Aug 3, 2026

NatWest is a hyper-profitable banking powerhouse trading at a deep discount, leveraging massive structural hedge tailwinds and wealth management M&A to drive explosive shareholder returns, though its reliance on UK interest rates poses a long-term margin headwind.

Score
90
Ambev S.A.
ABEV·Consumer Staples
A ★★★★Buy
Current$3.11
Target$3.50
Return+12.5%
Aug 3, 2026

Ambev blends dominant South American market share and digital B2B innovations with high return on invested capital, presenting a compelling thesis despite FX volatility and evolving Brazilian tax regimes.

Score
86
ASE Technology Holding Co., Ltd.
ASX·Technology
A ★★★★Buy
Current$35.17
Target$45.00
Return+28.0%
Aug 2, 2026

Riding the explosive structural demand for AI advanced packaging, ASE Technology secures massive margin expansion and revenue growth, though heavy capacity-building capital expenditures will temporarily suppress free cash flow.

Score
91
ING Groep N.V.
ING·Financials
A ★★★★Buy
Current$34.93
Target$39.50
Return+13.1%
Aug 2, 2026

Armed with an impregnable low-cost deposit moat and scaling agentic AI, ING offers explosive 17% ROTE profitability and massive share buybacks, though structural dependence on ECB rate policy caps terminal upside.

Score
91
APi Group Corporation
APG·Industrials
A ★★★★Buy
Current$39.68
Target$53.51
Return+34.9%
Aug 2, 2026

APi Group is successfully transforming into a high-margin, recurring-revenue powerhouse insulated by strict fire safety regulations and turbocharged by the data center supercycle, though investors must meticulously monitor the execution risks tied to its aggressive $1 billion international M&A spree and elevated $3.55 billion debt load.

Score
86
Regeneron Pharmaceuticals, Inc.
REGN·Healthcare
A ★★★★Buy
Current$762.63
Target$963.85
Return+26.4%
Aug 2, 2026

Regeneron offers massive structural upside through Dupixent's explosive growth and a newly debt-free Sanofi profit-share agreement, while the market's hyper-fixation on Eylea biosimilar erosion has irrationally compressed the valuation to deep-value territory.

Score
90
MasTec, Inc.
MTZ·Industrials
A ★★★★Buy
Current$312.44
Target$505.00
Return+61.6%
Aug 2, 2026

MasTec is a dominant, under-the-radar AI infrastructure play poised for massive earnings acceleration via its $21.4B backlog and Superior Group buyout, provided it can swiftly remedy near-term cash burn and telecom margin compression.

Score
85
Haleon plc
HLN·Healthcare
A ★★★★Buy
Current$9.87
Target$11.60
Return+17.5%
Aug 2, 2026

Haleon is an elite, cash-gushing consumer health compounder that has successfully deleveraged and shed its legacy corporate overhangs, positioned to drive relentless margin expansion and massive shareholder returns despite near-term macroeconomic volume pressures.

Score
87
The Cigna Group
CI·Healthcare
A ★★★★Buy
Current$284.30
Target$365.40
Return+28.5%
Aug 2, 2026

Cigna's elite cash-flow generation and extreme valuation discount offer a massive margin of safety, though near-term margin compression from its transition to a transparent, rebate-free PBM model requires investor patience.

Score
90
Intercontinental Exchange, Inc.
ICE·Financials
A ★★★★Buy
Current$152.48
Target$185.00
Return+21.3%
Aug 2, 2026

ICE pairs an impenetrable, wide-moat energy and financial derivatives monopoly with a rapidly expanding, high-margin recurring data and software business, though investors must monitor the FTC integration risks and elevated debt load from the $5.7B MarketAxess acquisition.

Score
91
Bristol-Myers Squibb Company
BMY·Healthcare
A ★★★★Buy
Current$65.31
Target$82.50
Return+26.3%
Aug 2, 2026

The explosive 15% expansion of the Growth Portfolio and a deeply discounted 9.2x forward P/E provide a massive margin of safety, completely offsetting the known headwinds of the impending 2028 Eliquis and Opdivo patent cliffs.

Score
86
Nextpower Inc.
NXT·Technology
A ★★★★Buy
Current$100.03
Target$135.00
Return+35.0%
Aug 2, 2026

Nextpower’s unmatched bankability and asset-light cash generation make it the dominant beneficiary of the solar supercycle, though the looming expiration of U.S. tax credits poses a long-term demand headwind.

Score
88
Mastercard Incorporated
MA·Financials
A ★★★★Buy
Current$573.10
Target$650.00
Return+13.4%
Aug 2, 2026

Mastercard's unparalleled toll-bridge network and explosive growth in high-margin software services (VAS) virtually guarantee long-term EPS compounding, though legislative threats (CCCA) and escalating bank rebates cap the near-term multiple expansion.

Score
89
Ferrari N.V.
RACE·Consumer Discretionary
A ★★★★Buy
Current$393.87
Target$461.10
Return+17.1%
Aug 2, 2026

Ferrari's absolute pricing power, 39% EBITDA margins, and massive personalization revenue guarantee long-term compounding, though its 37x P/E multiple demands flawless execution through the upcoming EV transition.

Score
87
Yum! Brands, Inc.
YUM·Consumer Discretionary
A ★★★★Buy
Current$157.00
Target$180.00
Return+14.6%
Aug 2, 2026

Yum! Brands combines an impenetrable global asset-light moat with aggressive share buybacks and a newly optimized portfolio, yet remains vulnerable to macro franchisee fatigue in a high interest rate environment.

Score
85
First Solar, Inc.
FSLR·Technology
A ★★★★Buy
Current$211.03
Target$330.00
Return+56.4%
Aug 2, 2026

The company commands a virtually impenetrable domestic moat and guarantees explosive compounding via an immense IRA-backed backlog, yet it remains intensely vulnerable to sudden political regime changes that could strip away the subsidies propelling its massive gross margins.

Score
87
Rio Tinto Group
RIO·Materials
A ★★★★Buy
Current$96.85
Target$122.09
Return+26.1%
Aug 2, 2026

Rio Tinto pairs an impenetrable, cash-printing iron ore moat with highly discounted, transformative copper growth, though investors must navigate the perpetual geopolitical volatility of its expansion jurisdictions and Chinese macro-dependence.

Score
92
UBS Group AG
UBS·Financials
A ★★★★Buy
Current$52.76
Target$61.50
Return+16.6%
Aug 2, 2026

The unprecedented scale of the post-merger wealth management monopoly is driving immense cost synergies and massive share buybacks, heavily outweighing the lingering threats of Swiss regulatory capital hikes and legacy litigation.

Score
85
Newmark Group, Inc.
NMRK·Real Estate
A ★★★★Buy
Current$15.08
Target$19.50
Return+29.3%
Aug 2, 2026

Newmark is a severely undervalued, cash-gushing real estate powerhouse perfectly positioned to exploit the upcoming $582 billion CRE debt maturity wall, though its success remains tethered to the stabilization of Federal Reserve interest rate policy.

Score
92
GFL Environmental Inc.
GFL·Industrials
A ★★★★Buy
Current$41.37
Target$49.50
Return+19.7%
Aug 2, 2026

GFL combines the irreplaceable scarcity of landfill monopolies with relentless margin-expanding M&A to generate immense cash flow, offering extreme downside protection via a highly credible take-private buyout floor.

Score
91
WEC Energy Group, Inc.
WEC·Utilities
A ★★★★Buy
Current$115.77
Target$135.00
Return+16.6%
Aug 1, 2026

Riding an unprecedented 45% localized demand shock driven by Microsoft and Vantage data centers, WEC will translate a $37.5B capital plan into guaranteed 7-8% EPS growth.

Score
87
Old Dominion Freight Line, Inc.
ODFL·Industrials
A ★★★★Buy
Current$212.47
Target$245.00
Return+15.3%
Aug 1, 2026

Old Dominion Freight Line combines unmatched operating efficiency (70.1% operating ratio) and pricing discipline with robust capacity investments, establishing an unassailable moat that continuously compounds intrinsic value despite macroeconomic headwinds.

Score
86
Agnico Eagle Mines Limited
AEM·Materials
A ★★★★Buy
Current$150.75
Target$169.54
Return+12.5%
Aug 1, 2026

Agnico Eagle offers unparalleled, risk-free leverage to the gold supercycle with its pristine balance sheet and $1.3B quarterly cash flow, though investors must monitor execution risks surrounding its $2.8B Hope Bay build and the Barnat pit recovery.

Score
86
GE HealthCare Technologies Inc.
GEHC·Healthcare
A ★★★★Buy
Current$69.94
Target$85.02
Return+21.6%
Aug 1, 2026

GE HealthCare is a high-moat MedTech oligopolist offering massive margin expansion potential through its PDx segment and SaaS integration, offset only by temporary supply chain inflation and hospital CapEx cycle risks.

Score
87